Novel Microdevices
Developer of a portable, battery-powered, cartridge-based sample-to-answer PCR platform intended to enable rapid molecular testing at the point of care. The organization focuses on assay development, independent performance validation, and establishing manufacturing capability for microfluidic cartridges and instruments. The platform and associated assay panels are in development and currently offered for research use only.
Industries
Nr. of Employees
small (1-50)
Novel Microdevices
Patents
Sample-to-answer microfluidic system and method including vertical microfluidic device and automated actuation mechanisms
US-12370544-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
US-12151239-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
US-11364495-B2
View DetailsSample processing device comprising magnetic and mechanical actuating elements using linear or rotational motion and methods of use thereof
US-11260392-B2
View Details
Sample-to-answer microfluidic system and method including vertical microfluidic device and automated actuation mechanisms
US-12370544-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
US-12151239-B2
View DetailsAutomated point-of-care devices for complex sample processing and methods of use thereof
US-11364495-B2
View DetailsSample processing device comprising magnetic and mechanical actuating elements using linear or rotational motion and methods of use thereof
US-11260392-B2
View DetailsProducts
Portable cartridge-based sample-to-answer PCR instrument (development)
A portable, battery-capable instrument designed to run integrated single-use cartridges for automated nucleic acid extraction and multiplex real-time PCR with cloud connectivity; intended for point-of-care and field deployment (research use only; product in development).
Single-use room-temperature-stable microfluidic cartridges (development)
Cartridges that integrate sample intake, magnetic bead extraction, and PCR reagents formulated for ambient stability; intended for multiple assay panels (STI, respiratory, global health).
Cloud-based instrument portal (My Novel Dx)
Web portal providing real-time instrument status, test results, usage reports, and patient data access for instrument users.
sample-to-answer diagnostic platform
Innovative microfluidic cartridges used in Novel Microdevices' sample-to-answer diagnostic platform enabling 15-minute PCR tests for infectious diseases like Flu, RSV, COVID-19, and STIs.
Novel Dx
A proprietary and best-in-class Point-of-Care (POC) rapid molecular diagnostics system that is ultra-portable and can be produced for a wide range of high-volume molecular diagnostic assay applications. It is designed for portability, weighing only four pounds, and is battery-powered, making it suited for low resource settings and low-and middle-income countries (LMICs). The system uses polymerase chain reaction (PCR) technology on a disposable cartridge to analyze genetic sequences for pathogen identification and antibiotic resistance detection.
high-performance, point-of-care RT-PCR platform
A high-performance, point-of-care RT-PCR platform that rapidly detects RSV, Influenza A, Influenza B, and COVID-19 in just 15 minutes.
Portable cartridge-based sample-to-answer PCR instrument (development)
A portable, battery-capable instrument designed to run integrated single-use cartridges for automated nucleic acid extraction and multiplex real-time PCR with cloud connectivity; intended for point-of-care and field deployment (research use only; product in development).
Single-use room-temperature-stable microfluidic cartridges (development)
Cartridges that integrate sample intake, magnetic bead extraction, and PCR reagents formulated for ambient stability; intended for multiple assay panels (STI, respiratory, global health).
Cloud-based instrument portal (My Novel Dx)
Web portal providing real-time instrument status, test results, usage reports, and patient data access for instrument users.
sample-to-answer diagnostic platform
Innovative microfluidic cartridges used in Novel Microdevices' sample-to-answer diagnostic platform enabling 15-minute PCR tests for infectious diseases like Flu, RSV, COVID-19, and STIs.
Novel Dx
A proprietary and best-in-class Point-of-Care (POC) rapid molecular diagnostics system that is ultra-portable and can be produced for a wide range of high-volume molecular diagnostic assay applications. It is designed for portability, weighing only four pounds, and is battery-powered, making it suited for low resource settings and low-and middle-income countries (LMICs). The system uses polymerase chain reaction (PCR) technology on a disposable cartridge to analyze genetic sequences for pathogen identification and antibiotic resistance detection.
high-performance, point-of-care RT-PCR platform
A high-performance, point-of-care RT-PCR platform that rapidly detects RSV, Influenza A, Influenza B, and COVID-19 in just 15 minutes.
Services
Development of multiplex molecular assays and conversion of validated assays to cartridge-ready formats for a portable PCR platform.
Provision of white papers and technical performance reports from independent evaluations for prospective customers and partners.
Development of multiplex molecular assays and conversion of validated assays to cartridge-ready formats for a portable PCR platform.
Provision of white papers and technical performance reports from independent evaluations for prospective customers and partners.
Expertise Areas
- Point-of-care molecular diagnostics
- Assay development and cartridgeization
- Clinical performance evaluation and external validation
- Microfluidic cartridge design and manufacturing
Key Technologies
- Real-time quantitative PCR (qPCR/RT-PCR)
- Magnetic bead nucleic acid extraction
- Microfluidic cartridge systems
- Multiplex fluorescence detection (multi-channel)
News & Updates
External performance evaluation of the platform for simultaneous detection of SARS-CoV-2, Influenza A/B, and RSV conducted at Emory University under NIH RADx funding; reported limits of detection on par with or exceeding laboratory PCR platforms (research setting).
State grant to support establishment of a GMP-compliant pilot manufacturing facility for production of microfluidic cartridges used in the platform.
Announcement of follow-on funding from NIH RADx program supporting continued development and validation of the point-of-care RT-PCR platform.
Follow-on funding after completion of critical performance milestones for a high-performance point-of-care RT-PCR platform targeting respiratory viruses.
Announcement of multi-million dollar funding from CARB-X to support development of rapid point-of-care molecular diagnostics for STIs and antibiotic-resistant infections.
Over $11 million awarded in competitive non-dilutive grants and awards from NIH, CARB-X, and state agencies.
External performance evaluation of the platform for simultaneous detection of SARS-CoV-2, Influenza A/B, and RSV conducted at Emory University under NIH RADx funding; reported limits of detection on par with or exceeding laboratory PCR platforms (research setting).
State grant to support establishment of a GMP-compliant pilot manufacturing facility for production of microfluidic cartridges used in the platform.
Announcement of follow-on funding from NIH RADx program supporting continued development and validation of the point-of-care RT-PCR platform.
Follow-on funding after completion of critical performance milestones for a high-performance point-of-care RT-PCR platform targeting respiratory viruses.
Announcement of multi-million dollar funding from CARB-X to support development of rapid point-of-care molecular diagnostics for STIs and antibiotic-resistant infections.
Over $11 million awarded in competitive non-dilutive grants and awards from NIH, CARB-X, and state agencies.